Sign In
glob
Find HeartFlow

HeartFlow Joins The Board Challenge as Newest Pledge Partner

Press Release

HeartFlow Joins The Board Challenge as Newest Pledge Partner

theBoardlist and Valence will support HeartFlow’s search for a Black director

NEW YORK, August 23, 2021 — The Board Challenge, a movement to increase the number of Black directors on U.S corporate boards, announced today that HeartFlow has signed on as a Pledge Partner, committing to add a Black director to its board within the next 12 months. HeartFlow, the leader in precision heart care, provides non-invasive, personalized cardiac tests and associated software suite solutions to address heart disease, the leading cause of death in the world.

HeartFlow will leverage resources from The Board Challenge including Valence and theBoardlist to identify top candidates for the open board seat.

“I am delighted to welcome HeartFlow to The Board Challenge,” said Sheryl Hilliard Tucker, executive director of The Board Challenge. “We are always looking for new companies willing to step up and take tangible action to diversify their boards, and make a difference in the overall makeup of U.S. boardrooms.”

HeartFlow joins a roster of Pledge Partner companies committed to diversifying their boards, including Quickbase, Accolade and PagerDuty. To date, 15 of the initiative’s Pledge Partners have elected a total of 17 new Black directors. The Board Challenge has 75+ Partners and Supporters in total working across industries to make board diversity a business imperative.

“We believe HeartFlow’s non-invasive, artificial intelligence-enabled solution can transform and democratize cardiovascular care by providing physicians with the information they need to make precise diagnoses and optimize treatment for their patients,” said John H. Stevens, MD, President, CEO and Co-Founder, HeartFlow. “We look forward to working with The Board Challenge to identify a Black director who can help us accomplish our mission of making HeartFlow accessible to more patients and providers.”

The Board Challenge invites all public and private U.S. companies to join the movement. Companies without a Black director can take the pledge and leverage our resources and network to assist in their search, while companies that have at least one Black director can sign on as Charter Partners and connect other organizations to The Board Challenge.

For more information and to take the pledge or express your support, reach out to join@theboardchallenge.org.

About HeartFlow

HeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. For more information, visit www.heartflow.com.

About The Board Challenge

The Board Challenge is a movement to increase representation and accelerate progress for Black board directors at public and private U.S. companies. The initiative was founded in September 2020 by Brad Gerstner (CEO, Altimeter Capital), Sukhinder Singh Cassidy (Founder and Chair, theBoardlist) and Guy Primus (CEO, Valence Community). Companies that take the pledge commit to adding at least one Black director to their board within 12 months, and can leverage resources from theBoardlist and Valence to enhance the search process, including a free, custom slate of top candidates.

For media inquiries, contact:

The Board Challenge
media@theboardchallenge.org

HeartFlow
media@heartflow.com

cert logo hitrust.7394f2b.cda83af2e008d8cc68f55103dbde7712

The information provided by the HeartFlow FFRCT Analysis, RoadMap Analysis, and Plaque Analysis from the HeartFlow ONE platform and the HeartFlow Planner is intended to be used in conjunction with the patient's clinical history, symptoms and other diagnostic tests, as well as the clinician's professional judgment. The HeartFlow FFRCT Analysis, RoadMap Analysis, Plaque Analysis and HeartFlow Planner may not be appropriate for all patients. See their respective indications for use for more information. The HeartFlow FFRCT Analysis has received FDA Clearance, is CE-Marked, and is commercially available in the United States, Europe, Japan and Canada. The RoadMap Analysis and Plaque Analysis have received FDA Clearance and are commercially available in the United States. The HeartFlow Planner has received FDA Clearance and is commercially available in the United States.

© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます！

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.